EXTON, Pa., Jan. 3 /PRNewswire-FirstCall/ -- ViroPharma Incorporated today announced it will present at the 25th Annual JP Morgan Healthcare Conference at 1:30 P.M. PT on Thursday, January 11, 2007. The conference is being held at Westin St. Francis, in San Francisco.
Michel de Rosen, ViroPharma’s president and chief executive officer, will discuss the Company’s goals and select financial guidance for 2007 as well as highlight 2006 achievements.
ViroPharma’s presentation will be webcast live for investors through http://www.viropharma.com and available through January 31, 2007. Please note that investors will be directed to the JP Morgan event website to access the webcast and will be required to register. Visitors are encouraged to register 5 minutes before scheduled presentation time. Also, immediately following the live webcast, it will take approximately 24 hours for the archived webcast to become available.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/pulvules_pi.pdf). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company’s website at http://www.viropharma.com.
ViroPharma Incorporated
CONTACT: William C. Roberts, Director, Corporate Communications,+1-610-321-6288, or Robert A. Doody, Manager, Corporate Communications,+1-610-321-6290, both of ViroPharma Incorporated
